The efficacy of TP chemotherapy combined with karelizumab on the postoperative clinical status of patients with advanced ovarian cancer

To investigate the efficacy of TP (Toripalimab Plus) chemotherapy combined with karelizumab in treatment advanced ovarian cancer after surgery. We recruited 96 patients who were admitted to our hospital between December 2019 and 2022 treated by tumor cell reduction The randomly divided into groups using a digital table, 48 each. control group was chemotherapy, while observation karelizumab. compared two regards adverse reactions levels VEGF (Vascular Endothelial Growth Factor), MMP-9 (matrixmetalloproteinase 9), CEA (A Carcinoma Embryonic Antigen), AFP (alpha-fetoprotein), CA125 (carbohydrate antigen 125), CA19-9 19-9) T lymphocytes. There no significant difference (p > 0.05); lower. data before within same (all p < CEA, AFP, lower than those group, differences CD3+ (cluster differentiation 3+) CD4+ higher, CD8+ group. 0.05). combination had positive impact on postoperative effectively regulating immune function markers. This protocol is safe can be selected considering specific situation individual patients.